Bioactive Salen-type Schiff Base Transition Metal Complexes as Possible Anticancer Agents

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Biochemistry

Background:

• Metal-based anticancer drugs show efficacy but suffer from non-selectivity and toxicity, limiting clinical use.
• Development of novel metal complexes with improved selectivity and reduced side effects is crucial for cancer therapy.
• Schiff base transition metal complexes offer a promising scaffold for developing new anticancer agents.

Purpose of the Study:

• To predict the potency and interaction modes of salen type Schiff base transition metal complexes.
• To evaluate these complexes against key proteins involved in cancer, including HDAC7, HDAC2, CatB, B-RAF kinase, TopII, RNR, TS, and rHA.
• To identify potential metallodrugs for cancer treatment through computational docking.

Main Methods:

• Utilized computational docking to predict binding affinities and interactions.
• Synthesized and characterized salen type Schiff base transition metal complexes.
• Assessed interactions against a panel of cancer-related protein targets.

Main Results:

• All investigated metal complexes demonstrated higher affinity for Histone Deacetylase 7 (HDAC7) compared to other targets.
• Bromo-derivatives of copper complexes exhibited superior activity against HDAC7.
• These bromo compounds also showed significant interactions with Kinase, Ribonucleotide Reductase (RNR), Thymidylate Synthase (TS), and Cathepsin B (CatB).
• Histone Deacetylase 2 (HDAC2) was identified as a less favorable target.
• Hydrophobic interactions were found to be essential for the activity of the metal complexes against protein targets.

Conclusions:

• Salen type Schiff base transition metal complexes, particularly bromo-copper derivatives, show potential as anticancer agents targeting HDAC7.
• The study provides valuable insights into the structure-activity relationships for developing novel metallodrugs.
• Further optimization and development of these enzyme inhibitors could lead to new therapeutic agents for cancer treatment.